Pro-Dex (PDEX) PT Set at $20.00 by Ascendiant Capital Markets

Ascendiant Capital Markets set a $20.00 target price on Pro-Dex (NASDAQ:PDEX) in a research note released on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Separately, ValuEngine raised shares of Pro-Dex from a hold rating to a buy rating in a research note on Monday, February 4th.

PDEX stock opened at $13.94 on Tuesday. The firm has a market cap of $56.47 million, a PE ratio of 17.38 and a beta of 1.07. Pro-Dex has a 52-week low of $6.05 and a 52-week high of $17.95. The company has a quick ratio of 4.60, a current ratio of 5.88 and a debt-to-equity ratio of 0.23.

In other news, Director David Hovda sold 2,700 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $14.34, for a total transaction of $38,718.00. Following the completion of the sale, the director now directly owns 800 shares in the company, valued at $11,472. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Kirk Richard Lee Van, Jr. acquired 3,500 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were purchased at an average price of $13.25 per share, with a total value of $46,375.00. Following the completion of the transaction, the chief executive officer now owns 24,897 shares of the company’s stock, valued at $329,885.25. The disclosure for this purchase can be found here. Insiders have sold 52,639 shares of company stock valued at $879,209 in the last ninety days. Insiders own 41.70% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in shares of Pro-Dex by 3.7% in the 1st quarter. Renaissance Technologies LLC now owns 47,300 shares of the medical instruments supplier’s stock worth $685,000 after purchasing an additional 1,700 shares during the period. O Shaughnessy Asset Management LLC bought a new position in shares of Pro-Dex in the 1st quarter worth approximately $242,000. Dimensional Fund Advisors LP lifted its stake in shares of Pro-Dex by 151.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 38,156 shares of the medical instruments supplier’s stock worth $552,000 after purchasing an additional 23,011 shares during the period. Wells Fargo & Company MN bought a new position in shares of Pro-Dex in the 1st quarter worth approximately $47,000. Finally, Advisor Group Inc. bought a new position in shares of Pro-Dex in the 1st quarter worth approximately $82,000. Institutional investors own 10.51% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services.

Featured Story: What are catch-up contributions?

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.